HOME >> BIOLOGY >> NEWS
Clinical study reports findings of combination therapy with DOXIL

Bridgewater, NJ (May 8, 2003) Results from a new study evaluating the combination of DOXIL (doxorubicin HCl liposome injection), vincristine and a reduced-dose dexamethasone, known as DVd, in patients with multiple myeloma were published in the November 15, 2002 issue of the journal Cancer. The study examined the efficacy, safety and convenience of the DVd regimen. Vincristine, a cancer chemotherapeutic, and dexamethasone are often given in combination with other drugs.

The Phase II study, conducted at the Cleveland Clinic Myeloma Research Program of the Taussig Cancer Center, investigated the safety, tolerability and efficacy of the DVd combination regimen in 33 patients with newly-diagnosed multiple myeloma. In the study, patients received at least six cycles of the DVd regimen. During each cycle, patients were administered intravenous (IV) DOXIL (40 mg/m2) and vincristine (2 mg) on the first day, and oral or intravenous dexamethasone (40 mg/day) for four days. This treatment regimen was repeated every four weeks.

Eighty-eight percent (29 patients) responded to treatment with the DVd regimen. Of these patients, four (12%) achieved a complete response, defined as complete disappearance of myeloma protein from the serum and urine by immune fixation, a bone marrow biopsy demonstrating less than 3% plasma cells, the absence of monoclonal plasma cells by immune staining of the bone marrow on two occasions at least four weeks apart, and no evidence of progressive disease by any other parameters. Eighteen patients (55%) had a major response, defined as a 50 percent or greater decrease of myeloma protein from the serum and urine, while seven patients (21%) had a minor response, defined as a decrease in bone pain, an improvement of performance status by one grade, and a reduction in serum myeloma protein of 25 percent or greater. The median time to progression in the study was 23.1 months with two-year and three-year progression-free survival rat
'"/>


8-May-2003


Page: 1 2 3 4 5 6

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
9. Clinical trial shows timing of chemotherapy improves survival in breast cancer
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/19/2020)... ... March 17, 2020 , ... ... microbiome populations down to the strain level, recently unveiled a convenient new solution ... kit contains the same innovative amplification capabilities as the Shoreline Complete kit. It ...
(Date:3/11/2020)... LAUDERDALE, Fla. (PRWEB) , ... March 11, 2020 ... ... Accredited teleradiology and telemedicine company backed by Siemens Healthineers and several healthcare VC ... already infected over 100,000 people in over 100 countries and has caused over ...
(Date:3/5/2020)... SAN DIEGO (PRWEB) , ... ... ... Inc. today announces the formation of its Scientific Advisory Board (SAB) comprised ... prestigious academic institutions, immune-oncology centers, cell therapy centers, and private industry. Cytonus ...
Breaking Biology News(10 mins):
(Date:4/1/2020)... ... 31, 2020 , ... Bedoukian Research, Inc. (BRI) ... Development Agreement that builds on each company’s expertise in developing efficient routes to ... supply of high-quality insect pheromones as well as flavors and fragrances. P2 has ...
(Date:3/13/2020)... ... 2020 , ... Today, DuPont Nutrition & Biosciences (DuPont) announced ... pioneer in the field of microbiome science, which focuses on microbes that live ... based at University College Cork and Teagasc Moorepark. , Representatives from both organizations ...
(Date:3/4/2020)... ... March 04, 2020 , ... ... of recombinant antibody products and services, today announced the launch of its ... rapidly express a large number of antibodies at 80 ml scale. All ...
(Date:2/28/2020)... ... 2020 , ... Designed primarily for laboratory and industrial use, ... thus simplifying setup, streamlining integration, and optimizing workflow. Capable of recording FHD (1080p) ... new HS Series cameras to be released. The HS Series includes cameras with ...
Breaking Biology Technology:
Cached News: